CVXGA 1
Alternative Names: BLB-101; CVXGA; CVXGA 1 - Blue Lake Biotechnology; Intranasal Parainfluenza Virus Type 5-SARS CoV-2 S Vaccine; PIV5-SARS CoV-2 vaccineLatest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator CyanVac
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 09 Dec 2024 Phase-II clinical trials in COVID-2019 infections (Prevention) (Intranasal)
- 25 Nov 2024 Immunogenicity, efficacy and adverse events data from phase II clinical trials in COVID-2019 infections released by CyanVac
- 16 Jul 2024 CyanVac completes phase II clinical trials in COVID-2019 infections (Prevention) in USA (Intranasal) (NCT05736835)